The role of PPAR gamma agonists - rosiglitazone and 15-deoxy- Δ12,14-prostaglandin J2 in experimental cyclosporine A hepatotoxicity.

The role of PPAR gamma agonists - rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J2 in experimental cyclosporine A hepatotoxicity. J Physiol Pharmacol. 2019 Dec;70(6): Authors: Sikora-Wiorkowska A, Smolen A, Czechowska G, Wiorkowski K, Korolczuk A Abstract Cyclosporine A (CsA) is an immunosuppressive drug used in transplantation and treatment of autoimmune diseases. Experimental studies revealed impairments in liver function and morphology among cyclosporine-treated animals. The aim of the study was to evaluate hepatoprotective activity of peroxisome-proliferator-activated receptors γ (PPARγ) ligands: rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J2 (PGDJ2) on CsA-induced hepatotoxicity in experimental animals. CsA was administered subcutaneously at a dose of 15 mg/kg/day for 28 days. Both PPARγ agonists were given for 28 days 0.5 hour before the administration of CsA. Rosiglitazone was administered orally at a dose of 8 mg/kg/day and PGDJ2 was given intraperitoneally at a dose of 30 μg/kg/day. CsA induced liver injury was evidenced by increased serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin. Concentrations of glutathione (GSH) and glutathione disulfide (GSSG), lipid peroxidation products, nicotinamide adenine dinucleotide+/nicotinamide adenine dinucleotide hydrogen (NAD+/NADH), nicotinamide adenine dinucleotide phosphate+/nicotinamide adenine dinucleotide phosphate hydrogen (...
Source: Journal of Physiology and Pharmacology - Category: Drugs & Pharmacology Tags: J Physiol Pharmacol Source Type: research